The coronavirus pandemic caused tremendous problems for the global economy. Private as well as governmental organizations are working round the clock to address this problem. Moreover, they want to create an effective vaccine to prevent such issues in the future. The biotechnology company from the U.S. successfully conducted an early-stage human trial for a coronavirus vaccine. This company is Moderna. Moreover, this information helped to boost its shares on May 18.
Importantly, 45 people took part in this process and they received two doses of the potential vaccine via intramuscular injection approximately 28 apart. Moreover, the vaccine also produced neutralizing antibodies against the COVID-19 in at least eight participants.
People should take into consideration that neutralizing antibodies appear to be important when it comes to acquiring protection.
Moderna and its achievement
According to scientists, antibodies provide some degree of protection against getting COVID-19. Nevertheless, it will take time to learn more about this topic. Unfortunately, at the moment there are no formally approved treatments for this disease.
The number of confirmed cases continues to rise and surpassed 4.8 million. The U.S. officials said it would at least 12 to 18 months to produce the vaccine.
According to the World Health Organization, more than 100 vaccines are under development in different parts of the world. Also, at least eight vaccines are in human trials.
Nevertheless, the company from Massachusetts was the first one to release data on a human trial testing a coronavirus vaccine. Importantly, the company works with the National Institutes of Health to develop a vaccine.
Last but not least, Moderna expects to begin a phase 3 trial in July. Moreover, if the vaccine is found to be effective as well as safe to use, it would be ready in early 2021. Hopefully, companies, as well as governments, are willing to invest in the vaccine.